The t1/2 of teduglutide, a GLP-2 analogue, which is a candidate for the treatment of short bowel syndrome (SBS) in two phase III clinical studies [5], is 2.99 h in male patient [6]. Here, GCG is linked to macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.